Form D · Biotechnology
HEMOSHEAR THERAPEUTICS, LLC
Charlottesville, VA · CIK 0001442720
Offering snapshot reported Feb 20, 2020 · SEC filing
- Reported sold
- $2.28M Offering amount: $4M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 5, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 20, 2020 | Initial | $2,281,000 | No comparison | 4 | SEC filing |
| Aug 14, 2018 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Jun 2, 2017 | Amendment | $800,000 | $500,000vs May 22, 2017 | 5 | SEC filing |
| May 22, 2017 | Initial | $300,000 | No comparison | 2 | SEC filing |
| Apr 3, 2017 | Amendment | $2,640,562 | No comparison | 26 | SEC filing |
| Feb 3, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 10, 2014 | Initial | $2,528,412 | No comparison | 24 | SEC filing |
| Apr 4, 2012 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Sep 13, 2010 | Initial | $250,000 | No comparison | 3 | SEC filing |
| Apr 15, 2009 | Initial | $150,000 | No comparison | Not reported | SEC filing |
| Aug 11, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-361010
Securities offered are convertible notes.
Source: Form D, filed Feb 20, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vincent E. Aurentz | Executive |
| Brett R. Blackman | Director, Executive |
| John L. Brooks, Iii | Director |
| Frederick W. K. Brown | Director |
| Brian M. Campbell | Director, Executive |
| Robert J. Gould | Director |
| Nicole Hastings | Executive |
| Mark Hayes | Executive |
| Aric Holsinger | Executive |
| Brian A. Johns | Executive |
| Mehmood A. Khan | Director |
| Kathleen M. Metters | Director |
| James C. Powers | Director, Executive |
| Sandra Rojas Caro | Executive |
| Jonathan M. Sackier | Director |
| W. Mc Ilwaine Thompson, Jr. | Director |
| William Mc Ilwaine Thompson, Jr. | Executive |
| Brian R. Wamhoff | Executive |
| H. Thomas Watkins | Director |
| H. Thomas Watkins, Iii | Director |
| Richard O. White | Executive |
| Reginald F. Woods | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
501 Locust Avenue Suite 301
Charlottesville, VA, 22902
Charlottesville, VA, 22902